CLINICAL RESEARCH: MYOCARDITIS
Myocardial Expression of Fas and Recovery of Left Ventricular Function in Patients With Recent-Onset Cardiomyopathy
Richard Sheppard, MD*,
Maninder Bedi, MD ,
Toru Kubota, MD, PhD ,
Marc J. Semigran, MD ,
William Dec, MD ,
Richard Holubkov, PhD||,
Arthur M. Feldman, MD, PhD¶,
Warren D. Rosenblum, MD#,
Charles F. McTiernan, PhD ,
Dennis M. McNamara, MD ,* for the IMAC Investigators
* McGill University, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Canada
Cardiovascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Cardiovascular Medicine, Kyushu University, Fukuoka, Japan
Massachusetts General Hospital, Boston, Massachusetts
|| Department of Family and Preventive Medicine, School of Medicine, University of Utah, Salt Lake City, Utah
¶ Department of Medicine, Jefferson Medical College, Philadelphia, Pennsylvania
# New York Medical College, Valhalla, New York
Manuscript received March 4, 2005;
revised manuscript received April 27, 2005,
accepted May 3, 2005.
* Reprint requests and correspondence: Dr. Dennis M. McNamara, Heart Failure/Transplantation Program, Cardiovascular Institute, University of Pittsburgh Medical Center, 566 Scaife Hall, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213 (Email: mcnamaradm{at}upmc.edu).
OBJECTIVES: This study aimed to evaluate the role of gene expression for predicting myocardial recovery in recent-onset cardiomyopathy.
BACKGROUND: Apoptosis may limit ventricular recovery. We examined the myocardial expression of Fas, Fas ligand (FasL), tumor necrosis factor (TNF)-alpha, and TNF receptor 1 (TNFR1), and myocardial recovery in patients from the multicenter Intervention in Myocarditis and Acute Cardiomyopathy (IMAC) study.
METHODS: Endomyocardial biopsy samples were obtained in 20 patients with recent-onset (<6 months) idiopathic dilated cardiomyopathy (left ventricular ejection fraction [LVEF] 0.40). The LVEF was assessed at baseline and at 6 and 12 months by nuclear scans. Myocardial expression was assessed by ribonuclease (RNase) protection, normalized to a constitutively active gene (glyceraldehydes 3-phosphate dehydrogenase [GAPDH]) and reported as percent GAPDH expression. The change in LVEF at 6 and 12 months was compared by tertiles of expression.
RESULTS: For all patients (14 men, 6 women; age 46.5 ± 10.7 years), the mean LVEF was 0.28 ± 0.05 at baseline and 0.40 ± 0.14 at six months. Patients in the highest tertile of Fas expression had minimal improvement at six months ( EF = 0.03 ± 0.05) when compared with the intermediate ( EF = 0.10 ± 0.13) and lowest tertiles ( EF = 0.21 ± 0.11, change in LVEF by tertile, p = 0.006). A similar relationship was seen with TNFR1 expression (highest tertile, EF = 0.06 ± 0.07; lowest tertile, EF = 0.21 ± 0.11, p = 0.02). In contrast with Fas and TNFR1, expression of TNF-alpha and FasL did not predict recovery of LV function.
CONCLUSIONS: In cardiomyopathy of recent onset, increased expression of Fas and TNFR1 was associated with minimal recovery of LV function. Apoptosis limits myocardial recovery, and represents a potential target for therapeutic intervention.
|
Abbreviations and Acronyms
| | ACEI = angiotensin-converting enzyme inhibitor | | FasL = Fas ligand | | FLICE = Fas-associated death domain-like interleukin-1ß-converting enzyme | | GAPDH = glyceraldehydes 3-phosphate dehydrogenase | | IMAC = Intervention in Myocarditis and Acute Cardiomyopathy study | | LVEF = left ventricular ejection fraction | | NYHA = New York Heart Association | | RNA = ribonucleic acid | | TNF = tumor necrosis factor | | TNFR = tumor necrosis factor receptor |
|
This article has been cited by other articles:

|
 |

|
 |
 
L. T. Cooper Jr.
Myocarditis
N. Engl. J. Med.,
April 9, 2009;
360(15):
1526 - 1538.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Zurney, K. E. Howard, and B. Sherry
Basal Expression Levels of IFNAR and Jak-STAT Components Are Determinants of Cell-Type-Specific Differences in Cardiac Antiviral Responses
J. Virol.,
December 15, 2007;
81(24):
13668 - 13680.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. N. Skouri, G. W. Dec, M. G. Friedrich, and L. T. Cooper
Noninvasive Imaging in Myocarditis
J. Am. Coll. Cardiol.,
November 21, 2006;
48(10):
2085 - 2093.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. E. Marchlinski and M. Jessup
Timing the Implantation of Implantable Cardioverter-Defibrillators in Patients With Nonischemic Cardiomyopathy
J. Am. Coll. Cardiol.,
June 20, 2006;
47(12):
2483 - 2485.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. DeMaria, O. Ben-Yehuda, D. Berman, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, D. Sahn, and S. Tsimikas
Highlights of the Year in JACC 2005
J. Am. Coll. Cardiol.,
January 3, 2006;
47(1):
184 - 202.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. L. Mann
Determinants of Myocardial Recovery in Myocarditis: Has the Time Come for Molecular Fingerprinting?
J. Am. Coll. Cardiol.,
September 20, 2005;
46(6):
1043 - 1044.
[Full Text]
[PDF]
|
 |
|
|